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Innate host defense pathways consist of microbial sensors, their signaling pathways, and the antimicrobial
effector mechanisms. Several classes of host defense pathways are currently known, each comprising
several pattern-recognition receptors that detect different types of pathogens. These pathways interact
with one another in a variety of ways that can be categorized into cooperation, complementation, and
compensation. Understanding the principles of these interactions is important for better understanding of
host defense mechanisms, as well as for correct interpretation of immunodeficient phenotypes.Introduction
The last decade has seen tremendous progress in the elucida-
tion of innate immune recognition mechanisms. Several families
of pattern recognition receptors have now been characterized
and established to function as sensors of microbial infections
(see reviews by Elinav et al., 2011; Kawai and Akira, 2011; Osorio
and Reis e Sousa, 2011; and Loo and Gale, 2011 in this issue of
Immunity). A common feature of these receptors is their ability to
trigger signaling pathways that activate innate antimicrobial and
inflammatory responses. In addition, these receptors induce
a set of requisite signals for activation of T and B cells, thus
coupling microbial recognition with the initiation of adaptive
immune responses.
Although the functions of different families of pattern recogni-
tion receptors are increasingly well characterized, their specific
contributions to host defense from infections are still being
defined and are often a subject of debate. This is due in part to
incomplete knowledge of the host protection mechanisms, and
in part due to differences in the interpretation of the existing
experimental and clinical data.
Here, we will discuss the functional interactions of different
host defense pathways and the contribution of these interactions
to host protection and susceptibility to infections.Innate Host Defense Pathways
The innate host defense pathways consist of microbial sensors,
their signaling pathways, and the effector mechanisms they
induce. The effector mechanisms fall into three broad cate-
gories: inflammatory mediators, antimicrobial effectors, and
signals inducing adaptive immune responses.
The best-known microbial sensors are pattern recognition
receptors, including Toll-like receptors (TLRs), nucleotide oligo-
merization domain (NOD) proteins, C-type lectin receptors
(CLRs), and RIG-I-like receptors (RLRs). Microbial sensors that
are not based on pattern recognition also exist, although they
have not yet been extensively characterized. Upon recognition
of their microbial ligands, pattern recognition receptors activate
signal transduction pathways that generally converge on severalkey transcription factors including nuclear factor (NF)-kB, acti-
vator protein 1 (AP1), interferon regulatory factors (IRFs), and
nuclear factor of activated T cells (NFAT) (Lee and Kim, 2007).
These transcription factors often function in combination with
each other to turn on the expression of several classes of genes,
including antimicrobial effectors; cytokines and chemokines that
orchestrate inflammatory and innate immune responses; and
genes involved in the induction of adaptive immunity. In addition,
pattern recognition receptors can induce transcription-indepen-
dent responses, such as degranulation, phagocytosis, chemo-
taxis, and activation of the nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase. Some microbial sensors do not
directly control gene expression, but rather initiate extracellular
host defense responses. For example, pentraxins, mannan-
binding lectin, and ficolins can activate complement pathways
upon binding to pathogen surfaces. Finally, certain microbial
receptors, such as macrophage receptor with collagenous
structure (MARCO) and macrophage mannose receptor, are
involved in bacterial phagocytosis (Elomaa et al., 1995), but
presumably do not activate gene expression on their own.
It is important to note that most pathogens can be detected by
more than one microbial sensor. Thus, bacterial pathogens can
be recognized by several TLRs, NODs, phagocytic receptors,
a complement system, inflammasomes, and in some cases
intracellular DNA sensors. Fungal pathogens can be detected
by TLRs, Dectins, the complement, and inflammasomes. Viral
pathogens can be detected by TLRs as well as intracellular
RNA and DNA sensors, and in some cases, by inflammasomes
(see reviews in this issue). Thus, the innate immune system has
a great deal of apparent redundancy at the level of pathogen
detection.Antimicrobial Effector Mechanisms
Once the microbial sensors become activated by pathogens,
they induce a broad array of antimicrobial defense mechanisms.
These defense mechanisms fall into several broad categories,
depending on the pathogen class as well as the identity of the in-
fected cell types and tissue compartments.Immunity 34, May 27, 2011 ª2011 Elsevier Inc. 629
Table 1. Effector Mechanism Categories
Defense Strategy Effector Class Pathogen Type
blocking pathogen entry
into the host organism
epithelial and mechanical barriers, IgA,
AMPs, mucins, cilia-mediated expulsion
most pathogens
blocking entry into host cells neutralizing antibodies bacteria, viruses
blocking pathogen spread coagulation, vasoconstriction, neutralizing antibodies most pathogens
direct killing of pathogen AMPs, BPI, lysozymes, proteases, acidic pH
(lysosomes and stomach), complement, ROS and RNS
most pathogens
direct killing of infected host cell IFN-a/b, NK cells, CTLs, ADCC viruses, intracellular
bacteria, protozoa
expulsion of pathogen IgE production, release of soluble mediators
(leukotrienes, prostaglandins and histamine),
mucus secretion, smooth muscle cell contraction,
cilia-mediated expulsion
multicellular parasites
nutrient deprivation NRAMP, lactoferrin, lipocalin, calprotectin
(iron and zinc), IDO (tryptophan)
bacteria, protozoa
AMPs, antimicrobial peptides; IgA, immunoglobulin A; BPI, bacterial permeability increasing protein; ROS, reactive oxygen species; RNS, reactive
nitrogen species; ADCC, antibody-dependent cellular cytotoxicity; IFN-a/b, type I interferons; CTL, cytotoxic T lymphocyte; IgE, immunoglobulin E;
NRAMP, natural resistance-associated macrophage proteins; and IDO, indoleamine 2,3-dioxygenase.
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IFN-b), which induce expression of over 200 antiviral genes
that can interfere with multiple stages of viral infection cycles
and sensitize infected cells to killing by cytotoxic NK cells and
CD8+ T cells. In addition, type I IFNs promote cytotoxic activity
of NK and CD8+ T cells and induce an antiviral state in neigh-
boring cells (Stetson andMedzhitov, 2006). Importantly, all these
responses can be induced by any of the viral pathogen sensors
as their signaling pathways converge on IRF3 and/or 7 activation
and type I IFN production (Honda and Taniguchi, 2006).
An important difference exists between IFN induction by cell-
intrinsic sensors, such as RLRs and cytosolic DNA sensors,
and cell-extrinsic mechanisms mediated by TLR3, TLR7, TLR8,
and TLR9. Cell-intrinsic sensors are ubiquitous and trigger
IFN-b production in infected cells, whereas the TLRs involved
in viral recognition are expressed on specialized cells, such as
plasmacytoid dendritic cells (pDCs), which make large amounts
of IFN-a in infected tissues. The common strategy of host
defense against viral pathogens is to interfere with viral replica-
tion and spread and to kill infected cells, often with the help of
cytotoxic lymphocytes (NK cells and CD8+ T cells). This latter
strategy is particularly useful in tissues with a high rate of
renewal, such as the epithelium. The cell types that cannot be
easily replaced, such as neurons and cardiomyocytes, may
rely on alternative mechanisms of antiviral defense, which
remain to be fully characterized.
Detection of bacterial, fungal, and protozoan pathogens by
multiple receptors results in the induction of antimicrobial
peptides (e.g., defensins and cathelicidins) and enzymes (e.g.,
iNOS, NADPH oxidase, lysozymes and proteases), as well as
proteins involved in deprivation of iron (NRAMP, lactoferrin, lipo-
calins) and tryptophan (IDO). Macrophages and neutrophils,
acute phase proteins, the complement system as well as surface
epithelia producing mucins and antimicrobial peptides, all
contribute to host defense against bacterial, fungal, and proto-
zoan infections. Importantly, these effector mechanisms can
be induced by multiple microbial sensors (TLRs, NODs, and630 Immunity 34, May 27, 2011 ª2011 Elsevier Inc.Dectins) through the NF-kB and MAP kinase signaling pathways
or by cytokines induced downstream of these pathways. The
common strategy of host defense against the majority of bacte-
rial, fungal, and protozoan pathogens is their direct killing by
antimicrobial effectors and the generation of an uninhabitable
microenvironment (low pH, nutrient deprivation).
Mechanisms of innate immune recognition of multicellular
parasites are not yet understood. Pattern recognition in this
case may be limited to a few parasitic products, such as chitin
(Reese et al., 2007). The main mechanism of recognition may
rely on detection of parasite-derived enzymatic activities, such
as cysteine proteases that are secreted by parasitic worms.
The defense strategy against multicellular parasites can vary
depending on their life stage. At the larval stage they can be
targeted and killed by toxic products of eosinophils (ROS and
major basic protein). At the adult stage, efficient parasite killing
may be limited by their size and the high potential of host tissue
damage. Therefore, the main defense strategy is to reduce their
entry into the host (by promoting the barrier function of mucosal
epithelia), to minimize their spread throughout the host (through
vasoconstriction and coagulation), and to promote their expul-
sion from the host (by peristalsis, mucus production, vomiting,
diarrhea, epithelial ciliary movement, and other mechanisms).
The main targets of the immune response against adult
parasites, therefore, are the host tissues in the infected compart-
ment, particularly mucosal epithelium, smooth muscles, and
endothelium. These tissues are activated by inflammatory medi-
ators induced upon parasitic infections including IL-13, hista-
mine, and bradykinin, which are also responsible for allergic
reactions after chronic exposure to allergens.
The summary of host defense strategies and the examples of
effector mechanisms involved are shown in Table 1. Even a brief
survey of antimicrobial effectors illustrates the high degree of
apparent functional redundancy within each of the defense cate-
gories. Before we consider the reasons for these functional
redundancies, we need to discuss the causes of diversity of
effector mechanisms.
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Most pathogens can be recognized by multiple microbial
sensors, which in turn can induce multiple antimicrobial effector
mechanisms. There are several reasons for the existence of
diverse recognition and effector responses. The existence of
multiple pathogen detecting pathways allows for a greater
‘‘coverage’’ of the microbial world, whereas diversity and redun-
dancy of the effectors accounts for robustness of host defenses
in the face of continuous pathogen evolution. Clearly different
sensors and effectors have evolved to detect and eliminate
different classes of pathogens, for example, RNA viruses versus
tape worms. However, there are additional evolutionary causes
of the diversity of host defense mechanisms. First, different
defense mechanisms operate in different tissues and body
compartments. The anatomy and physiology of different tissues
may dictate which defensemechanisms can and cannot be used
(Matzinger and Kamala, 2011). In general, host physiology can
affect the repertoire of available host defenses. For example,
amphibian skin is an important organ for gas exchange, and
therefore it lacks a cornified keratinocyte layer. As a result,
amphibians do not have an important physical barrier to
pathogen entry, which in turn caused an elaboration of a highly
potent antimicrobial peptide defense in the skin. This type of
physiological constraints and evolutionary compensation is
likely to be commonplace. Another example of how host biology
may affect the diversity of immune defenses is provided by
comparison of the immune response genes in Drosophila or
Anopheles and the honeybee. The honeybee genome contains
only about a third of the genes known to be involved in immunity
in the fruit fly (Honeybee Genome Sequencing Consortium,
2006). The honeybees have effective social immunity mecha-
nisms, such as pathogen avoidance, social grooming, and nest
hygiene (Cremer and Sixt, 2009), which are absent in the nonso-
cial insects including fruit flies and mosquitoes. This may
account for reduced reliance on the immune defense mecha-
nisms that are essential in the Drosophila (Evans et al., 2006).
Another important factor accounting for the diversity of host
defense pathways emerged from the field of ecological immu-
nology. A key point here is that host defenses are associated
with fitness costs. There are two types of fitness costs: evolu-
tionary costs and maintenance costs (Sadd and Schmid-
Hempel, 2009). The evolutionary costs arise when development
of host defense mechanisms is negatively correlated with the
development of other physiological systems. For example,
evolution of antimicrobial defenses in the gut may have con-
strained the evolution of a more efficient digestive function.
Themaintenance costs arise whenever the defensemechanisms
are employed and include metabolic costs and immunopa-
thology. The metabolic costs of the immune response are well
appreciated in certain host species, for example in insects and
some birds. To what degree the metabolic costs constrain
immune defenses in mammals is less clear. Presumably, the
ability to store significant energy reserves in adipose tissues in
some animal species may alleviate these constrains to some
extent. The costs associated with immunopathology, on the
other hand, are likely to be universal (Graham et al., 2005). Impor-
tantly, the antimicrobial effector mechanisms differ widely in
terms of their fitness costs. Fitness costs are important to
consider for several reasons: First, they help to explain howhost defenses change over evolutionary time—the higher the
cost the more likely a given host defense pathway will be lost
whenever pathogen-induced selective pressure is removed or
reduced, or when the defense mechanism can be replaced by
other, less costly mechanisms. Second, fitness costs may
underlie an important regulatory strategy of host defenses: it
appears that in the course of an infection, less costly defenses
are induced first and only if they are insufficient, the defenses
with higher fitness costs are employed. Indeed, if we consider
the host defenses from this perspective, they form a spectrum
in terms of their fitness costs (for example, their ability to cause
immunopathology), that correlates with the order of their induc-
tion. The epithelial antimicrobial peptides and IgA secreted into
the lumen of the intestine probably have the lowest fitness costs
because their ability to cause tissue damage isminimal or nonex-
istent. Accordingly, these effector mechanisms are known to be
engaged constitutively. If their protective effects are insufficient,
however, the host engages activation of resident myeloid cells
that have increased microbicidal activity but also increased
tissue damage potential. If these defenses are still insufficient,
highly potent and damaging defenses (recruited neutrophils
and inflammatory monocytes, activated Th1 and Th17 cells)
are employed. Their tissue damage potential is the highest,
and they are induced as the last resort. Similarly, IgM and IgG1
antibodies are more easily inducible compared to IgG2 isotypes,
which, when induced, have higher potential to cause tissue
damage and autoimmunity. Thus the hierarchy of defensemech-
anisms, as defined by their fitness costs, dictates the order of
their induction during an infection, as well as the signal require-
ments for their induction, magnitude and duration. This logic is
likely to be applicable to most defense mechanisms of innate
and adaptive immunity.
It should be noted, however, that different types of fitness
costs are not necessarily at the same end of the spectrum:
host defenses with low tissue damage potential (e.g., secreted
IgA) can have high metabolic cost (in part because they are
continuously engaged), whereas reactive oxygen species
production by NADPH oxidase has lower metabolic cost but
higher tissue damaging potential. The net fitness cost is
a complex product of different types of maintenance costs and
is likely to be different in different hosts depending on environ-
ment- and host-specific physiological constraints.
The discussion above illustrates that host defense mecha-
nisms differ in multiple ways even though all are designed to
provide protection from infections. This heterogeneity is impor-
tant to consider when analyzing the contribution of the individual
pathways to protective immunity from infections. Analyses of
immunodeficient humans or mutant animals with defects in
specific pathways or effector mechanisms often give unex-
pected results that are not easily explained based on the current
understanding of immunity. Whatever the specific reasons might
be, host resistance or susceptibility to infection is a product of
functional interactions between different host defense path-
ways, which we will discuss next.
Interactions of Host Defense Pathways
In principle, host defense pathways can engage in three types of
interactions: cooperation, complementation, and compensation
(Figure 1).Immunity 34, May 27, 2011 ª2011 Elsevier Inc. 631
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Figure 1. Different Types of Host Pathway
Interactions
There are three different types of host pathway
interactions: cooperation, complementation, and
compensation: (A) cooperating pathways induce
the same effector mechanism more efficiently
when engaged simultaneously; (B) complement-
ing pathways induce distinct effector mechanisms
(EM1 and EM2), which complement each other to
form one functional unit; and (C) compensation
between two pathways occurs when one pathway
is deficient and the other intact. Compensation
can take place at the level of sensors (C, top), or at
the level of effectors (C, bottom). ‘‘P’’ refers to
pathogens, ‘‘A’’ and ‘‘B’’ refer tomicrobial sensors,
and ‘‘EM’’ refers to effector mechanisms.
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two (or more) individual pathways optimally induce the same
effector mechanism when both pathways are activated
(Figure 1A). An example of cooperation is the induction of
optimal TNF-a production by macrophages when both TLR2
and Dectin-1 are engaged (Osorio and Reis e Sousa, 2011).
Another example is the cooperation between bactericidal
permeability increasing protein (BPI) and defensins, which
together have a synergistic bactericidal effect. For quantitative
effects, cooperation often results in synergy.
Complementation is a type of interaction where individual
pathways activate distinct effector mechanisms, which comple-
ment each other to form a functional unit of defense (Figure 1B).
An example of complementation is the interaction between the
antibodies and phagocytes: both effectors can function inde-
pendently, but can complement each other to form a functional
unit of antibody-mediated phagocytosis.
Compensation is a type of functional interactions that occurs
when one of the host defense pathways is inactivated (for
example, due to a mutation) while the other pathway(s) inducible
by the same infection remain intact. Compensation can be of two
types depending on whether it occurs at the level of sensors or
effectors (Figure 1C). Thus, two sensors can compensate for
each other if they can both activate the same effector mecha-
nism (Figure 1C, top). Alternatively, two sensors may activate
distinct effector responses, but if these responses are individu-
ally sufficient to have a given effect (such as host protection),
they will compensate for each other (Figure 1C, bottom). There
are many examples of the first type of compensation because
multiple sensors can activate the same effector responses:
TLR4 and NODs can induce the same antibacterial peptides;
TLR7 and RIG-I can both activate the type-I IFN response, and
so on. An example of the second type of compensation could
be activation of NADPH oxidase and iNOS by distinct sensors,
provided that activation of either enzyme is sufficient to protect
against a given pathogen.632 Immunity 34, May 27, 2011 ª2011 Elsevier Inc.Unlike cooperation and complementa-
tion, compensation only becomes ap-
parent when one of the host defense
pathways is inactivated by mutations or
by the pathogen (for example, as a result
of immune evasion strategy). Under-
standing the rules of compensation is im-portant for correct interpretation of infectious disease outcomes,
as illustrated in the next section.
Immune Compensation and Susceptibility to Infections
When a particular host defense pathway is disabled by muta-
tions, as happens in experimental animals and immunodeficient
patients, infection susceptibility will depend on whether the
defect can be compensated for by the remaining pathways
(Figure 2). If pathogen Px can be detected by two sensors, A
and B, that can both activate a protective effector response,
inactivation of pathway A (due to mutation or by pathogen
evasion mechanisms) can be compensated by pathway B and
the host will remain resistant to pathogen Px (Figure 2A).
However, the same host can be susceptible to pathogen Py
that is detected by pathway A only (Figure 2B). A clinical
outcome of immunodeficiency in pathway A would be suscepti-
bility to pathogen Py but not Px and the incorrect conclusion
would be that pathway A plays a role in defense against path-
ogenPy but notPx. The correct interpretation of the same clinical
observation, however, is that pathway B can compensate for
a defect in A in response to Px but not Py because Py does not
activate pathway B.
In the second type of compensation, pathogen Px is detected
by two pathways, A and B, that activate distinct effector mech-
anisms: EM1 and EM2, respectively. When pathway A is inacti-
vated, the host will be protected from pathogen Px if EM2 is suffi-
cient for protection (Figure 2C) and susceptible to pathogen Py if
EM2 is insufficient (Figure 2D). Patients with pathway A mutation
would be protected from pathogen Px and susceptible to path-
ogen Py. This clinical presentation may lead to an incorrect
conclusion that sensor A is irrelevant for protection from Px
when in fact a defect in A is compensated by EM2. If Px can
evade recognition by sensor B, however (Figure 2C), the
outcome will be that sensor A is critical for protection from Px.
More generally, immune evasion from a given host defense
pathway can obscure the role of this pathway in pathogen
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Figure 2. Compensation between Host
Defense Pathways and Its Role in Infectious
Disease Phenotypes
Defect in pathway A can be compensated by
pathway B in the case of pathogen Px (A), but not
in the case of pathogen Py (B). Defect in EM1 can
be compensated by EM2 if EM2 is sufficient to
provide protection against pathogen Px (C). If EM2
is not sufficient to protect against Py, then EM2will
not compensate for EM1 deficiency (D). Solid lines
indicate intact pathways; dashed lines indicate
inactive pathways. Pathway deficiency can result
from mutations or can be due to pathogen
evasion.
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important role in defense against that pathogen, otherwise it
would not have evolved to avoid that pathway in the first place.
Clearly not all combinations of host defense pathways can
compensate for each other. Also, there are likely to be different
degrees of compensation. Presumably, defense mechanisms
that belong to the same category (Table 1) can compensate for
each other most efficiently. Compensation also depends on
characteristics of the pathogens, such as the combination of
pathogen-associated molecular patterns (PAMPs) they produce
and their evasion strategies. These host- and pathogen-specific
properties collectively define the rules of immunological
compensation that determine infectious disease susceptibility
in immunodeficient humans and mutant animals.
Similar considerations apply to the analysis of innate control of
adaptive immunity. If more than one innate sensing pathway can
lead to activation of the adaptive immune response to a given
pathogen (or immunization conditions), then none of them would
be required when more than one pathway can be activated by
a given pathogen or adjuvant. This can lead to an incorrect
conclusion that specific innate sensing pathways are not
required for activation of adaptive immunity (Gavin et al.,
2006), although a trivial explanation is the engagement of
compensating innate immune pathways that operate under
distinct experimental conditions. One example of this point is
a compensatory antibody response to commensal bacteria in
the absence of TLR-mediated defenses (Slack et al., 2009).
Consequences of Immune Compensation
As discussed above, defects in specific host defense pathways
can be compensated for by intact pathways if they meet certain
criteria. This is generally reflected in the infection susceptibility
spectrum observed in immunodeficient humans and mutant
animals. However, it should be noted that even in the presence
of compensating pathways that may provide protection, there
are often deleterious consequences of immunodeficiency.ImmunityThey may or may not have clinical mani-
festation and therefore may sometimes
go unnoticed. Paradoxically, one com-
mon consequence of immunodeficiency
can be immunopathology. The reason
for that can be illustrated as follows: if
there are two pathways (A and B in
Figure 3A) that can be activated in
response to a given pathogen, inactiva-tion of one of these pathways (pathway A in Figure 3B) due to
immunodeficiency will be compensated by the intact pathway
B. However, the intact pathway has to be hyperactivated to
provide protection in the absence of pathway A. This is because
pathway B has to ‘‘work alone’’ when pathway A is deficient, and
because pathway A deficiency can result in (at least transient)
increase in pathogen burden compared to the normal situation
when both pathways are intact. Thus, a decrease in AMPs
production by mucosal epithelia may result in increased mucus
production, which can affect respiratory or digestive function.
Similarly, a defect in innate effector mechanisms can result in
a compensatory increase in the adaptive immune response (as
long as it can be activated by an intact alternative innate sensing
pathway), which can also lead to immunopathology. In some
cases, this results in subclinical symptoms, but at the extreme
the enhanced activation of the compensatory adaptive immune
response can lead to autoimmunity. Indeed, it is well docu-
mented that immunodeficiencies (with the obvious exception
of SCIDs) are commonly associated with autoimmune diseases
(Arkwright et al., 2002). In experimental animals, this phenom-
enon is well recognized in the studies of colitis, which can be
caused by defective immune responses (Izcue et al., 2009).
It should be noted that a compensatory increase in pathway B,
when pathway A is disabled, can lead to an incorrect interpreta-
tion that the mutated gene from pathway A plays a negative
regulatory role in pathway B. Finally, the compensatory
enhancement of pathway B can be caused not only by genetic
immunodeficiency in pathway A, but also by evasion of geneti-
cally intact pathway A by a pathogen.
The immunopathological consequences of hyperactivation of
host defenses in the face of immunodeficiency also highlight
another reason why there are many seemingly redundant
effector mechanisms: different effector mechanisms activated
by a given infection can function efficiently in combination
without any individual pathway having to be activated to the
maximal level that will have the highest potential for34, May 27, 2011 ª2011 Elsevier Inc. 633
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Figure 3. Compensatory Enhancement of
Host Defense Pathways Can Result in
Immunopathology
If more than one pathway is induced by a given
infection, they can provide optimal protection with
minimal immunopathology, because they do not
have to be induced to a maximal level (A). If one
pathway is deficient, the intact pathway will have
to be induced to a higher level, thus increasing the
potential for tissue damage (B).
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mucus production, AMPs, IgA, and CTLs, each of these mecha-
nisms can work at the optimal range without going into ‘‘over-
drive.’’ If mucus production or CTLs were the only available
defense mechanisms, each would have to be activated to
a much greater extent and consequently might cause an unac-
ceptable level of immunopathology. Thus, distribution of protec-
tive mechanisms among different effector responses allows for
amore efficient defense withminimal immunopathology. In addi-
tion to immunopathology, other types of fitness costs may be
incurred by compensatory hyperactivation of defense mecha-
nisms, such as negative effects on metabolism or optimal tissue
functions. From the evolutionary standpoint, the most important
fitness cost is the negative effect on reproductive success. Even
a slight decrease in reproductive fitness can have a dramatic
effect on the evolutionary scale. However, these effects are
rarely considered in the studies of infections in experimental
animals or immunodeficient humans. Therefore, conclusions
that any particular host defense mechanism is ‘‘redundant’’ are
questionable in the absence of complete knowledge of their
effects outside the infectious disease itself.
Redundancy in Host Defenses
Redundancy is a notion that is often invoked in the literature,
when an expected phenotype is not observed in the absence
of a specific gene. It is sometimes implicitly appreciated that
redundancy is conditional on both the environment and the
readout. For example, the left arm is redundant for a chess
player, but not for a piano player. Similarly, many genes may
be redundant in an animal facility but not in the wild. Some
host defenses may be redundant with modern sanitation and
health care but not without them. Finally, some genes may be
redundant for human or animal survival from infections, but
nonredundant for their reproductive fitness. The ability of host
defenses to compensate for each other also often leads to
conclusions of redundancy, even though there are almost invari-
ably some fitness costs that are not properly evaluated.
The evolution of redundancy has been a subject of debate for
decades, as simple logic would suggest that true redundancy
would be evolutionarily unstable because there would be no
selective pressure to maintain it. Nowak and colleagues have
provided a theoretical analysis of redundancy in gene functions
and described several scenarios where redundancy can be
evolutionarily stable (Nowak et al., 1997). One of these scenarios634 Immunity 34, May 27, 2011 ª2011 Elsevier Inc.can be adapted for the discussion of
redundancy in host defenses (Figure 4):
let’s consider a pathogen Px that can be
detected by two microbial sensors, Aand B, that can both activate effector mechanism EM1, which
in turn can provide protection from Px. In this scenario, B would
be redundant when A is intact. However, if B has other functions,
such as activation of EM2, this additional function will maintain B
if there is a selective pressure to preserve EM2. Thus, A andB are
redundant upon infection with pathogen Px that can be detected
by both A and B, but not during an infection with the pathogen Py
that can only be detected by the sensor B. Whether sensor B is
essential or redundant would also depend onwhich pathogen Px
or Py is more common (see below). Clearly, the most common
pathogens are the components of normal microbiota—the
opportunistic pathogens that cause overt infection only in immu-
nocompromised humans and animals. Thus, a key issue con-
cerning the role of different host defense pathways in protection
from infections is the exposure rate to different types of patho-
gens, an issue that is not commonly considered in the analysis
of immunodeficiencies.
Immunodeficiency and Pathogen Exposure
The clinical outcome of immunodeficiency depends not only on
the function of the host defense pathway that is eliminated, but
also on the exposure rate to different pathogens and their
immune evasion strategies. For any given host organism, all
the potential pathogens form awide spectrum of exposure rates.
On one end of the spectrum are the opportunistic pathogens, for
which exposure rate is 100 percent. On the other end of the
spectrum are ‘‘accidental pathogens’’ for which exposure rate
can be close to zero, especially if they are endemic. For example,
most humans are exposed to Streptococcus pneumonia and
Staphylococcus aureus, which are components of a normal
microflora in the skin and the throat, but our exposure rate to
the Ebola virus is effectively zero. Most other pathogens fall
somewhere in between on the spectrum. The differences in
exposure rates can significantly affect our interpretation of the
infection susceptibility in immunodeficiencies. As discussed
above, mutation in pathway A (Figure 2A) can be compensated
for by pathway B for pathogen Px, but not for pathogen Py. If
Px is common and Py is rare, one could conclude that pathway
A is redundant because the majority of patients will be exposed
to Px and not to Py. If Py is more common, however, then the
conclusion could be that pathway A is essential. In this case,
whether pathway A is redundant or essential is a function of
exposure rates to Px versus Py. The exposure rates to Px and
Py could be very different in different environments, at different
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Figure 4. ‘‘Redundancy’’ in Host Defense Pathways Is Conditional on
the Nature of Infection
Pathways B is ‘‘redundant’’ when the host is exposed to pathogen Px, but
nonredundant when the host is exposed to pathogen Py. Pathways A and B
are redundant with regards to the common function (activation of EM1), but
nonredundant with regards to activation of EM2. Thus, conclusion of
‘‘redundancy’’ can be affected by both the exposure rates of Px and Py, and by
the ‘‘readout’’ (whether EM2 activation is measured or not).
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Perspectivestages of human evolution, and can depend on modern environ-
mental factors, such as availability of sanitation, vaccines, and
antibiotics.
Because opportunistic pathogens have the highest exposure
rates, they are the most common causes of infectious diseases
in immunodeficient people. However, the normal function of
the defective pathway cannot be correctly inferred on the basis
of most common pathogens alone, despite the fact that they
are most relevant clinically. We generally do not know what the
susceptibility would be to rare pathogens, and which pathogens
may have been common during different stages of evolution.
In addition to exposure rate, the evasion strategies used by
different pathogens can also affect the clinical outcomes of
immunodeficiency. One well-documented example of this
phenomenon is deficiency in the terminal complement compo-
nents, which commonly results in susceptibility to Neisseria
spp. N. meningitidis and N. gonorrhoeae are opportunistic path-
ogens, which is one factor accounting for the high incidence of
infections in complement immunodeficiency. However, comple-
ment is clearly an important host defense mechanism that plays
a role in many other infections as well. Why then is terminal
complement deficiency associated with such a narrow spectrum
of infections? The reason is likely that other defense mecha-
nisms can compensate for terminal complement defects in the
case of other common pathogens, but not in the case of
Neisseria spp. Why do not other defense mechanisms compen-
sate for complement defects in the case of Neisseria? The
reason most likely is because Neisseria has potent immune
evasion mechanisms against all other relevant host defense
pathways (Lo et al., 2009), making them ineffective in compen-
sating for complement defects.
Thus pathogen exposure rates, virulence and immune evasion
mechanisms can all affect the outcome of immunodeficient
states.Perspectives
Understanding the role of different host defense pathways in
protection from infections is often complicated and there is
debate on some fundamental issues, such as the role of different
innate sensing pathways in host defense and control of adaptiveimmunity. The underlying problem is that immunity and
infectious diseases are studied in three fields that use different
language and mind-sets: basic immunology, human immu-
nology and ecological immunology. Most of the available
fundamental knowledge is generated by experiments on model
organisms (such as inbred mice and fruit flies), where carefully
controlled mechanistic studies are possible. Studies of human
infectious diseases, including studies of human immunodefi-
ciencies, provide valuable information that is relevant to human
health. Finally, studies in ecological immunology examine
biology of infections in the natural context and reveal evolu-
tionary processes that account for disease resistance and
susceptibility. Each of these approaches has important limita-
tions: Studies in model animals, while well controlled, generally
rely on a limited set of read-outs (e.g., survival and/or pathogen
burden) and are performed in the unnatural environment of
animal facilities. Furthermore, unique aspects of biology of
model animals may preclude generalizations to other species.
Analysis of human infectious diseases and immunodeficiencies
is necessarily descriptive and cannot be controlled in the same
way as studies in model organisms. Human studies may also
have sample biases: First, the human subjects available for clin-
ical studies may not be representative of the entire human pop-
ulation because of unequal access to medical care, sanitation
and hygiene; and second, even patients accessible for analyses
may not be homogenous in terms of their genetics, nutrition,
microbiota, etc. For example, if a given immunodeficiency
results in 50 percent mortality from infections, it is generally
not knownwhether the survivors (or non-survivors) share another
mutation or polymorphism (or a symbiont) that may account for
their survival or mortality in the presence of the immunodefi-
ciency in question. The modern human environment is also
unnatural from the evolutionary standpoint: abnormally high
population density on the one hand, and access to antibiotics,
vaccination, sanitation, and hygiene products on the other
hand, are not exactly natural for human species in a sense that
much of human biology was shaped by an entirely different envi-
ronment. Finally, ecological immunology has many logistic
limitations of the field studies and is usually performed on
species that can be easily observed in their natural environment.
Ecological immunology provides a unique perspective on evolu-
tionary processes that shape the immune system, but unfortu-
nately most ‘mainstream’ immunologists are not familiar with
this field.
Thus all three subfields of study of infectious diseases have
their strengths and natural limitations. The future challenge is
to incorporate the knowledge from all three areas into a more
complete understanding of immunity and infectious diseases.ACKNOWLEDGMENTS
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